Ras inhibitors
US-2021130303-A1 · May 6, 2021 · US
Ras inhibitors
US11566007B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11566007-B2 |
| Application number | US-202017089035-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 4, 2020 |
| Priority date | Nov 4, 2019 |
| Publication date | Jan 31, 2023 |
| Grant date | Jan 31, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound, or a pharmaceutically acceptable salt thereof, selected from the following compounds: Ex # Structure A202 A248 A276 A277 A278 A279 A286 A287 A288 A314 A330 A331 A340 A347 A447 A468 A506 A520 A521 A694 A728 . 2. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of claim 1 , and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
- A61P35/00Primary
Antineoplastic agents · CPC title
- C07D245/04Primary
condensed with carbocyclic rings or ring systems · CPC title
Bridged systems · CPC title
in which the condensed system contains four or more hetero rings · CPC title
Bridged systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11566007B2 cover?
- The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
- Who is the assignee on this patent?
- Revolution Medicines Inc
- What technology area does this patent fall under?
- Primary CPC classification A61P35/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).